https://orcid.org/0000-0003-1275-6094
References
- Stepanek J, Blue RS, Parazynski S. Space medicine in the era of civilian spaceflight. N Engl J Med. 2019;380(11):1053–1060.
- Eyal S, Derendorf H. Medications in space: in search of a pharmacologist’s guide to the galaxy. Pharm Res. 2019;36(10):148.
- Wotring VE, Smith LK. Dose tracker application for collecting medication use data from international space station crew. Aerosp Med Hum Perform. 2020 Jan 1;91(1):41–45.
- Aunon-Chancellor SM, Pattarini JM, Moll S, et al. Venous thrombosis during spaceflight. N Engl J Med. 2020 Jan 2;382(1):89–90.
- Blue RS, Bayuse TM, Daniels VR, et al. Supplying a pharmacy for NASA exploration spaceflight: challenges and current understanding. NPJ Microgravity. 2019;5(1):14.
- Cintron NM, Putcha L, Chen Y-M, et al. Inflight salivary pharmacokinetics of scopolamine and dextroamphetamine. In: Bungo MW, Bagian TM, Bowman MA, et al., editors. NASA technical memorandum 58280. Results of the life sciences DSOs conducted aboard the space shuttle 1981-1986. Huston, TX: National Aeronautics and Space Administration; 1987. p. 25–29.
- Cintron NM, Putcha L, Vanderploeg JM, et al. Inflight pharmacokinetics of acetaminophen in saliva. In: Bungo MW, Bagian TM, Bowman MAeditors. NASA technical memorandum 58280. Results of the life sciences DSOs conducted aboard the space shuttle 1981-1986. Huston, TX: National Aeronautics and Space Administration; 1987. p. 19–23.
- Putcha L, Cintron NM. Pharmacokinetic consequences of spaceflight. Ann N Y Acad Sci. 1991 Feb 28;618:615–618.
- Kovachevich IV, Kondratenko SN, Starodubtsev AK, et al. Pharmacokinetics of acetaminophen administered in tablets and in capsules under long term space flight conditions. Pharm Chem J. 2009;43(3):130–133.
- Boyd J, Wang Z, Putcha L Bioavailability of promethazine during spaceflight. Tech. Rep. NASA/TM-2009-01322, NASA Johnson Space Center. [updated 2009 Jan 01; cited 2020 Feb 7]. Available from: https://ntrs.nasa.gov/search.jsp?R=20090001322.
- Putcha L, Kovachevich I Physiologic alterations and pharmacokinetic changes during space flight (2.3.1). [cited 2020 Feb 7]. Available from: https://lsda.jsc.nasa.gov/Experiment/exper/359.
- Frank J, Gonzalez FJ, Coughtrie M, et al. Drug Metabolism. In: Brunton LL, Hilal-Dandan R, Knollmann BC, editors. Goodman & Gilman’s: the pharmacological basis of therapeutics. New York: McGraw-Hill Medical; 2018. p. 13e.
- Crabbé A, Nielsen-Preiss SM, Woolley CM, et al. Spaceflight enhances cell aggregation and random budding in Candida albicans. PloS One. 2013;8(12):e80677.
- Morrison MD, Fajardo-Cavazos P, Nicholson WL. Comparison of Bacillus subtilis transcriptome profiles from two separate missions to the International Space Station. NPJ Microgravity. 2019 Jan 07;5(1):1.
- Zhang Y, Lu T, Wong M, et al. Transient gene and microRNA expression profile changes of confluent human fibroblast cells in spaceflight. Faseb J. 2016 Jun;30(6):2211–2224.
- Stingl JC, Welker S, Hartmann G, et al. Where failure is not an option -personalized medicine in astronauts. PloS One. 2015;10(10):e0140764.
- European Space Agency. Frequently asked questions – ESA astronauts. [ cited 2020 Feb 1]. Available from: https://www.esa.int/Science_Exploration/Human_and_Robotic_Exploration/Astronauts/Frequently_asked_questions_ESA_astronauts
- National Aeronautics and Space Administration. Pharm03: we do not know the extent to which spaceflight alters pharmacokinetics. [updated 2019 Jul 31; cited 2020 Mar 16]. Available from: https://humanresearchroadmap.nasa.gov/Gaps/gap.aspx?i=542
- Low LA, Giulianotti MA. Tissue chips in space: modeling human diseases in microgravity. Pharm Res. 2019;37(1):8.
- Amselem S. Remote controlled autonomous microgravity lab platforms for drug research in space. Pharm Res. 2019;36(12):183.